Top 5 Drug Type | Count |
---|---|
Small molecule drug | 19 |
Chemical drugs | 4 |
Prophylactic vaccine | 2 |
Non-degrading molecular glue | 1 |
Synthetic peptide | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date25 Jun 2018 |
Target |
Mechanism mTOR inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. Canada |
First Approval Date16 May 2008 |
Target |
Mechanism PR modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. Japan |
First Approval Date25 Jan 1956 |
Start Date01 May 2025 |
Sponsor / Collaborator |
Start Date01 Apr 2025 |
Sponsor / Collaborator |
Start Date01 Apr 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Mefunidone Hydrochloride ( TGF-β1 ) | Type 2 diabetes mellitus with established diabetic nephropathy More | Phase 2 |
Fluorofenidone ( TGF-β1 x p38γ ) | Hepatitis B, Chronic More | Phase 2 |
EEF2K inhibitors(Central South University) ( EEF2K ) | Triple Negative Breast Cancer More | Preclinical |
Tabersonine ( NLRP3 ) | Ovarian Cancer More | Preclinical |
Tannic Acid ( DAAO x IGF-1R x SARS-CoV-2 3CLpro x Serine protease ) | Respiratory Syncytial Virus Infections More | Preclinical |